Showing 8491-8500 of 10255 results for "".
- Sciton Expanding in Canadahttps://practicaldermatology.com/news/20120229-sciton_expanding_in_canada/2459860/Sciton, Inc., is establishing a direct presence in Canada. Noting a very strong and loyal customer base within Canada, the company says it views the Canadian market as an integral part of its corporate growth strategy. Sciton will expand its marketing, sales, clinical education and service offerings
- New Rosacea Gel Coming Soonhttps://practicaldermatology.com/news/20120202-new_rosacea_gel_coming_soon/2459871/SkinCeuticals will soon unveil its Redness Neutralizer, a lightweight gel cream that prevents redness by targeting environmental triggers of inflammation leading to the onset of rosacea. Formulated wi
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- Dr. Ted Rosen Highlights Oral Lesions in Dermatologyhttps://practicaldermatology.com/news/Dr-Ted-Rosen-Highlights-Oral-Lesions-Dermatology/2476037/Oral lesions represent a diagnostic challenge in dermatology due to their limited morphological variation and overlapping features across conditions. At the DEF Essential Resource Meeting 2025 (DERM2025), Theodore Rosen, MD, reviewed a broad spectrum of oral pathologies, from benign pigmentations
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag
- Hands On: Practical Tips for Diagnosing and Treating Chronic Hand Eczemahttps://practicaldermatology.com/news/hands-on-practical-tips-for-diagnosing-and-treating-chronic-hand-eczema/2475415/Despite its small body surface area involvement, chronic hand eczema (CHE) represents a significant dermatologic and socioeconomic burden. In a recent session on chronic hand eczema (CHE) Socity of Dermatology Physician Associates (SDPA) 2025 Summer Conference given by Adam Friedman, MD, FAAD, he
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- GALDA Co-Director Explains Organization's Work and Impacthttps://practicaldermatology.com/news/GALDA-Co-Director-Explains-Organizations-Work-Impact/2475171/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- INTEGUMENT-INFANT to Test Roflumilast Cream in Children Under Twohttps://practicaldermatology.com/news/integument-infant-to-test-roflumilast-cream-in-children-under-two/2475087/Arcutis Biotherapeutics has announced the enrollment of the first participants in its new phase 2 INTEGUMENT-INFANT study focusing on the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis (AD).
- Patent Issued for Coya’s IL-2 Technologyhttps://practicaldermatology.com/news/patent-issued-for-coyas-il-2-technology/2474992/Coya Therapeutics has received a new U.S. patent for proprietary methods of producing a highly stable liquid formulation (aldesleukin) of recombinant human interleukin-2 (rhIL-2), according to a press release from the manufacturer.